顺二氨二氯铂II治疗晚期乳腺癌的II期研究。两种给药方案。
A phase II study of cis-diamminedichloroplatinum II for advanced breast cancer. Two dose schedules.
作者信息
Martino S, Samal B A, Singhakowinta A, Yoshida S, Mackenzie M, Jain J, Vaitkevicius V K
出版信息
J Cancer Res Clin Oncol. 1984;108(3):354-6. doi: 10.1007/BF00390472.
Abstract
Thirty-six (36) women with metastatic breast cancer refractory to conventional therapies were treated with cis-diamminedichloroplatinum II. Two dose schedules were used sequentially. The first 15 patients received platinum at a dose of 15 mg/m2 daily for 5 days at 28-day intervals. No response was noted in this group. Subsequently, 21 patients were treated with a dose of 100-120 mg/m2 at 28-day intervals, but with additional induced diuresis with saline, furosemide, and mannitol. Among 13 patients evaluable for response, 2 partial responses were observed.
摘要
36例对传统疗法难治的转移性乳腺癌女性患者接受了顺二氯二氨铂II治疗。依次采用了两种给药方案。前15例患者接受的铂剂量为每日15mg/m²，连用5天，间隔28天。该组未观察到反应。随后，21例患者接受的剂量为100 - 120mg/m²，间隔28天，但额外使用生理盐水、速尿和甘露醇进行诱导利尿。在可评估反应的13例患者中，观察到2例部分缓解。
相似文献
1
A phase II study of cis-diamminedichloroplatinum II for advanced breast cancer. Two dose schedules.顺二氨二氯铂II治疗晚期乳腺癌的II期研究。两种给药方案。
J Cancer Res Clin Oncol. 1984;108(3):354-6. doi: 10.1007/BF00390472.
2
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.赞布替尼联合化疗作为HER2阳性晚期胃食管腺癌患者的一线治疗：一项多中心、单臂、2期研究的主要结果
Lancet Oncol. 2025 May 30. doi: 10.1016/S1470-2045(25)00287-6.
3
Bisphosphonates for breast cancer.用于乳腺癌的双膦酸盐类药物。
Cochrane Database Syst Rev. 2005 Jul 20(3):CD003474. doi: 10.1002/14651858.CD003474.pub2.
4
Platinum-containing regimens for metastatic breast cancer.转移性乳腺癌的含铂方案。
Cochrane Database Syst Rev. 2017 Jun 23;6(6):CD003374. doi: 10.1002/14651858.CD003374.pub4.
5
Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial.奥氮平5毫克联合三联止吐药用于含蒽环类方案治疗乳腺癌患者的总体疗效和安全性：一项3期、双盲、随机、安慰剂对照试验。
Lancet Oncol. 2025 Jun 17. doi: 10.1016/S1470-2045(25)00233-5.
6
Phase II evaluation of fractionated low and single high dose cisplatin in various tumors.分次低剂量和顺铂单次高剂量在多种肿瘤中的II期评估。
J Cancer Res Clin Oncol. 1984;107(1):57-60. doi: 10.1007/BF00395492.
7
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial.强化与标准剂量英夫利昔单抗诱导治疗对类固醇难治性急性重度溃疡性结肠炎（PREDICT-UC）的疗效：一项开放标签、多中心、随机对照试验。
Lancet Gastroenterol Hepatol. 2024 Nov;9(11):981-996. doi: 10.1016/S2468-1253(24)00200-0. Epub 2024 Sep 2.
8
Bisphosphonates for breast cancer.用于乳腺癌的双膦酸盐类药物。
Cochrane Database Syst Rev. 2002(1):CD003474. doi: 10.1002/14651858.CD003474.
9
Inhaled mannitol for cystic fibrosis.吸入用甘露醇治疗囊性纤维化。
Cochrane Database Syst Rev. 2018 Feb 9;2(2):CD008649. doi: 10.1002/14651858.CD008649.pub3.
10
Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study results.帕拉泽司琼，一种新型口服完全雌激素受体拮抗剂（CERAN）和选择性雌激素受体降解剂（SERD），用于雌激素受体阳性/人表皮生长因子受体2阴性晚期或转移性乳腺癌患者：1/2期研究结果。
Breast Cancer Res. 2025 Jul 1;27(1):119. doi: 10.1186/s13058-025-02049-y.
引用本文的文献
1
Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer Patients.转移性乳腺癌患者循环肿瘤细胞敏感性谱预测顺铂化疗反应的前瞻性评估
Front Oncol. 2021 Jun 25;11:697572. doi: 10.3389/fonc.2021.697572. eCollection 2021.
2
Triple-negative breast cancer: role of specific chemotherapy agents.三阴性乳腺癌：特定化疗药物的作用。
Cancer J. 2010 Jan-Feb;16(1):53-61. doi: 10.1097/PPO.0b013e3181d24ff7.
3
Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer.对接受过蒽环类药物和紫杉烷预处理的转移性乳腺癌患者每两周进行一次吉西他滨和顺铂化疗。
Invest New Drugs. 2008 Aug;26(4):363-8. doi: 10.1007/s10637-007-9110-3. Epub 2007 Dec 29.
4
Combinations of interferon with platinum complexes: synergistic and antagonistic effects on growth inhibition of MCF-7 and MDA-MB231 breast cancer cells.干扰素与铂配合物的组合：对MCF-7和MDA-MB231乳腺癌细胞生长抑制的协同和拮抗作用。
J Cancer Res Clin Oncol. 1994;120(5):286-92. doi: 10.1007/BF01236385.
5
Cisplatin and 5-fluorouracil in refractory breast cancer patients: a phase II study.
Breast Cancer Res Treat. 1988 Jul;11(3):269-71. doi: 10.1007/BF01807286.
6
Phase II study of deoxydoxorubicin in previously untreated metastatic breast cancer.
Breast Cancer Res Treat. 1990 Dec;17(2):139-43. doi: 10.1007/BF01806294.
7
Cisplatin and its analogues in the treatment of advanced breast cancer: a review.顺铂及其类似物在晚期乳腺癌治疗中的应用：综述
Br J Cancer. 1992 Jun;65(6):787-93. doi: 10.1038/bjc.1992.169.
本文引用的文献
1
2
Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer.
Cancer Chemother Pharmacol. 1983;11(2):108-12. doi: 10.1007/BF00254257.
3
New platinum complexes in clinical trials.
Cancer Treat Rev. 1983 Mar;10(1):39-51. doi: 10.1016/s0305-7372(83)80031-0.
4
Phase I study of high-dose cis-dichlorodiammineplatinum(II) with forced diuresis.大剂量顺式二氯二氨铂（II）联合强制利尿的I期研究。
Cancer Treat Rep. 1977 May-Jun;61(3):367-70.
Zotero 插件